Live vaccines after pediatric solid organ transplant: Proceedings of a consensus meeting, 2018

Sneha Suresh; Julia Upton; Michael Green; Anne Pham-Huy; Klara M. Posfay-Barbe; Marian G. Michaels; Karina A. Top; Yaron Avitzur; Catherine Burton; Pearlie P. Chong; Lara Danziger-Isakov; Anne I. Dipchand; Diane Hébert; Deepali Kumar; Shaun K. Morris; Nadya Nalli; Vicky Lee Ng; Sarah Kogan Nicholas; Joan L. Robinson; Melinda Solomon; Bruce Tapiero; Anita Verma; Jolan E. Walter; Upton D. Allen

doi:10.1111/petr.13571

Live vaccines after pediatric solid organ transplant: Proceedings of a consensus meeting, 2018

Sneha Suresh, Julia Upton, Michael Green, Anne Pham-Huy, Klara M. Posfay-Barbe, Marian G. Michaels, Karina A. Top, Yaron Avitzur, Catherine Burton, Pearlie P. Chong, Lara Danziger-Isakov, Anne I. Dipchand, Diane Hébert, Deepali Kumar, Shaun K. Morris, Nadya Nalli, Vicky Lee Ng, Sarah Kogan Nicholas, Joan L. Robinson, Melinda SolomonBruce Tapiero, Anita Verma, Jolan E. Walter, Upton D. Allen

Medicine

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

75 Citas (Scopus)

Resumen

Growing evidence suggests receipt of live-attenuated viral vaccines after solid organ transplant (SOT) has occurred and is safe and needed due to lapses in herd immunity. A 2-day consortium of experts in infectious diseases, transplantation, vaccinology, and immunology was held with the objective to review evidence and create expert recommendations for clinicians when considering live viral vaccines post-SOT. For consideration of VV and MMR post-transplant, evidence exists only for kidney and liver transplant recipients. For MMR vaccine post-SOT, consider vaccination during outbreak or travel to endemic risk areas. Patients who have received antiproliferative agents (eg. mycophenolate mofetil), T cell–depleting agents, or rituximab; or have persistently elevated EBV viral loads, or are in a state of functional tolerance, should be vaccinated with caution and have a more in-depth evaluation to define benefit of vaccination and net state of immune suppression prior to considering vaccination. MMR and/or VV (not combined MMRV) is considered to be safe in patients who are clinically well, are greater than 1 year after liver or kidney transplant and 2 months after acute rejection episode, can be closely monitored, and meet specific criteria of “low-level” immune suppression as defined in the document.

Idioma original	English
Número de artículo	e13571
Publicación	Pediatric Transplantation
Volumen	23
N.º	7
DOI	https://doi.org/10.1111/petr.13571
Estado	Published - nov. 1 2019

Nota bibliográfica

Funding Information:
We would like to acknowledge all conference attendees and author contributions to this endeavor. While the document will provide guidance to clinicians, the recommendations do not by themselves represent exclusive courses of action. We would like to thank the Transplant and Regenerative Medicine Centre (TRMC) at the Hospital for Sick Children for financial and administrative support for this initiative. Special thanks to Kathryn Breckbill, Christine Garner, and Susan Stinson‐Lypka for their assistance in making this initiative possible. All authors reviewed the document prior to publication.

Publisher Copyright:
© 2019 Wiley Periodicals, Inc.

ASJC Scopus Subject Areas

Pediatrics, Perinatology, and Child Health
Transplantation

PubMed: MeSH publication types

Consensus Development Conference
Journal Article

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.1111/petr.13571

Otros archivos y enlaces

Citar esto

Suresh, S., Upton, J., Green, M., Pham-Huy, A., Posfay-Barbe, K. M., Michaels, M. G., Top, K. A., Avitzur, Y., Burton, C., Chong, P. P., Danziger-Isakov, L., Dipchand, A. I., Hébert, D., Kumar, D., Morris, S. K., Nalli, N., Ng, V. L., Nicholas, S. K., Robinson, J. L., ... Allen, U. D. (2019). Live vaccines after pediatric solid organ transplant: Proceedings of a consensus meeting, 2018. Pediatric Transplantation, 23(7), Artículo e13571. https://doi.org/10.1111/petr.13571

Suresh, S, Upton, J, Green, M, Pham-Huy, A, Posfay-Barbe, KM, Michaels, MG, Top, KA, Avitzur, Y, Burton, C, Chong, PP, Danziger-Isakov, L, Dipchand, AI, Hébert, D, Kumar, D, Morris, SK, Nalli, N, Ng, VL, Nicholas, SK, Robinson, JL, Solomon, M, Tapiero, B, Verma, A, Walter, JE & Allen, UD 2019, 'Live vaccines after pediatric solid organ transplant: Proceedings of a consensus meeting, 2018', Pediatric Transplantation, vol. 23, n.º 7, e13571. https://doi.org/10.1111/petr.13571

@article{380daa8b74e94dc3921e9c252737e63f,

title = "Live vaccines after pediatric solid organ transplant: Proceedings of a consensus meeting, 2018",

abstract = "Growing evidence suggests receipt of live-attenuated viral vaccines after solid organ transplant (SOT) has occurred and is safe and needed due to lapses in herd immunity. A 2-day consortium of experts in infectious diseases, transplantation, vaccinology, and immunology was held with the objective to review evidence and create expert recommendations for clinicians when considering live viral vaccines post-SOT. For consideration of VV and MMR post-transplant, evidence exists only for kidney and liver transplant recipients. For MMR vaccine post-SOT, consider vaccination during outbreak or travel to endemic risk areas. Patients who have received antiproliferative agents (eg. mycophenolate mofetil), T cell–depleting agents, or rituximab; or have persistently elevated EBV viral loads, or are in a state of functional tolerance, should be vaccinated with caution and have a more in-depth evaluation to define benefit of vaccination and net state of immune suppression prior to considering vaccination. MMR and/or VV (not combined MMRV) is considered to be safe in patients who are clinically well, are greater than 1 year after liver or kidney transplant and 2 months after acute rejection episode, can be closely monitored, and meet specific criteria of “low-level” immune suppression as defined in the document.",

author = "Sneha Suresh and Julia Upton and Michael Green and Anne Pham-Huy and Posfay-Barbe, {Klara M.} and Michaels, {Marian G.} and Top, {Karina A.} and Yaron Avitzur and Catherine Burton and Chong, {Pearlie P.} and Lara Danziger-Isakov and Dipchand, {Anne I.} and Diane H{\'e}bert and Deepali Kumar and Morris, {Shaun K.} and Nadya Nalli and Ng, {Vicky Lee} and Nicholas, {Sarah Kogan} and Robinson, {Joan L.} and Melinda Solomon and Bruce Tapiero and Anita Verma and Walter, {Jolan E.} and Allen, {Upton D.}",

note = "Funding Information: We would like to acknowledge all conference attendees and author contributions to this endeavor. While the document will provide guidance to clinicians, the recommendations do not by themselves represent exclusive courses of action. We would like to thank the Transplant and Regenerative Medicine Centre (TRMC) at the Hospital for Sick Children for financial and administrative support for this initiative. Special thanks to Kathryn Breckbill, Christine Garner, and Susan Stinson‐Lypka for their assistance in making this initiative possible. All authors reviewed the document prior to publication. Publisher Copyright: {\textcopyright} 2019 Wiley Periodicals, Inc.",

year = "2019",

month = nov,

day = "1",

doi = "10.1111/petr.13571",

language = "English",

volume = "23",

journal = "Pediatric Transplantation",

issn = "1397-3142",

publisher = "Wiley-Blackwell",

number = "7",

}

TY - JOUR

T1 - Live vaccines after pediatric solid organ transplant

T2 - Proceedings of a consensus meeting, 2018

AU - Suresh, Sneha

AU - Upton, Julia

AU - Green, Michael

AU - Pham-Huy, Anne

AU - Posfay-Barbe, Klara M.

AU - Michaels, Marian G.

AU - Top, Karina A.

AU - Avitzur, Yaron

AU - Burton, Catherine

AU - Chong, Pearlie P.

AU - Danziger-Isakov, Lara

AU - Dipchand, Anne I.

AU - Hébert, Diane

AU - Kumar, Deepali

AU - Morris, Shaun K.

AU - Nalli, Nadya

AU - Ng, Vicky Lee

AU - Nicholas, Sarah Kogan

AU - Robinson, Joan L.

AU - Solomon, Melinda

AU - Tapiero, Bruce

AU - Verma, Anita

AU - Walter, Jolan E.

AU - Allen, Upton D.

N1 - Funding Information: We would like to acknowledge all conference attendees and author contributions to this endeavor. While the document will provide guidance to clinicians, the recommendations do not by themselves represent exclusive courses of action. We would like to thank the Transplant and Regenerative Medicine Centre (TRMC) at the Hospital for Sick Children for financial and administrative support for this initiative. Special thanks to Kathryn Breckbill, Christine Garner, and Susan Stinson‐Lypka for their assistance in making this initiative possible. All authors reviewed the document prior to publication. Publisher Copyright: © 2019 Wiley Periodicals, Inc.

PY - 2019/11/1

Y1 - 2019/11/1

N2 - Growing evidence suggests receipt of live-attenuated viral vaccines after solid organ transplant (SOT) has occurred and is safe and needed due to lapses in herd immunity. A 2-day consortium of experts in infectious diseases, transplantation, vaccinology, and immunology was held with the objective to review evidence and create expert recommendations for clinicians when considering live viral vaccines post-SOT. For consideration of VV and MMR post-transplant, evidence exists only for kidney and liver transplant recipients. For MMR vaccine post-SOT, consider vaccination during outbreak or travel to endemic risk areas. Patients who have received antiproliferative agents (eg. mycophenolate mofetil), T cell–depleting agents, or rituximab; or have persistently elevated EBV viral loads, or are in a state of functional tolerance, should be vaccinated with caution and have a more in-depth evaluation to define benefit of vaccination and net state of immune suppression prior to considering vaccination. MMR and/or VV (not combined MMRV) is considered to be safe in patients who are clinically well, are greater than 1 year after liver or kidney transplant and 2 months after acute rejection episode, can be closely monitored, and meet specific criteria of “low-level” immune suppression as defined in the document.

AB - Growing evidence suggests receipt of live-attenuated viral vaccines after solid organ transplant (SOT) has occurred and is safe and needed due to lapses in herd immunity. A 2-day consortium of experts in infectious diseases, transplantation, vaccinology, and immunology was held with the objective to review evidence and create expert recommendations for clinicians when considering live viral vaccines post-SOT. For consideration of VV and MMR post-transplant, evidence exists only for kidney and liver transplant recipients. For MMR vaccine post-SOT, consider vaccination during outbreak or travel to endemic risk areas. Patients who have received antiproliferative agents (eg. mycophenolate mofetil), T cell–depleting agents, or rituximab; or have persistently elevated EBV viral loads, or are in a state of functional tolerance, should be vaccinated with caution and have a more in-depth evaluation to define benefit of vaccination and net state of immune suppression prior to considering vaccination. MMR and/or VV (not combined MMRV) is considered to be safe in patients who are clinically well, are greater than 1 year after liver or kidney transplant and 2 months after acute rejection episode, can be closely monitored, and meet specific criteria of “low-level” immune suppression as defined in the document.

UR - http://www.scopus.com/inward/record.url?scp=85071930524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071930524&partnerID=8YFLogxK

U2 - 10.1111/petr.13571

DO - 10.1111/petr.13571

M3 - Article

C2 - 31497926

AN - SCOPUS:85071930524

SN - 1397-3142

VL - 23

JO - Pediatric Transplantation

JF - Pediatric Transplantation

IS - 7

M1 - e13571

ER -

Live vaccines after pediatric solid organ transplant: Proceedings of a consensus meeting, 2018

Resumen

Nota bibliográfica

ASJC Scopus Subject Areas

PubMed: MeSH publication types

ODS de las Naciones Unidas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto